Norbert Gattermann


Ontology type: schema:Person     


Person Info

NAME

Norbert

SURNAME

Gattermann

Publications in SciGraph latest 50 shown

  • 2022-03-09 Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis in ANNALS OF HEMATOLOGY
  • 2021-05-04 Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes in NATURE MEDICINE
  • 2021-03-11 Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial in LEUKEMIA
  • 2021-02-09 Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes in NATURE MEDICINE
  • 2020-11-07 Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes in ANNALS OF HEMATOLOGY
  • 2020-08-03 Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes in NATURE MEDICINE
  • 2019-08-09 Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients in BLOOD CANCER JOURNAL
  • 2018-08-04 Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy in ANNALS OF HEMATOLOGY
  • 2018-06-06 Iron Chelation in MYELODYSPLASTIC SYNDROMES
  • 2018-02-22 Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2017-11-25 Iron overload in myelodysplastic syndromes (MDS) in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2017-05-04 A retrospective study evaluating the impact of infectious complications during azacitidine treatment in ANNALS OF HEMATOLOGY
  • 2017-02-21 Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2017-02-20 Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study in LEUKEMIA
  • 2016-10-24 Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis in LEUKEMIA
  • 2016-06-22 Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians in ANNALS OF HEMATOLOGY
  • 2016-03-30 Causes of death in 2877 patients with myelodysplastic syndromes in ANNALS OF HEMATOLOGY
  • 2016-03-05 Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2015-12-15 Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) in LEUKEMIA
  • 2014-04-30 Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia in GENOME MEDICINE
  • 2013-11-04 Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients in LEUKEMIA
  • 2013-07-11 Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome in ANNALS OF HEMATOLOGY
  • 2013-03-29 Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells in LEUKEMIA
  • 2012-11-06 Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance in LEUKEMIA
  • 2012-10-17 Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload in ANNALS OF HEMATOLOGY
  • 2012-08-08 Anaesthesia in a patient with subarachanoidal haemorrhage and high oxygen affinity haemoglobinopathy (HB york): case report in BMC ANESTHESIOLOGY
  • 2012-07-05 Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study in LEUKEMIA
  • 2011-10-10 Trimodal therapy in squamous cell carcinoma of the esophagus in EUROPEAN JOURNAL OF MEDICAL RESEARCH
  • 2011-06-21 The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract in EUROPEAN JOURNAL OF MEDICAL RESEARCH
  • 2011-04-08 Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid in CLINICAL EPIGENETICS
  • 2010-10-12 Iron overload in MDS—pathophysiology, diagnosis, and complications in ANNALS OF HEMATOLOGY
  • 2009-05-22 Imatinib in breast milk in ANNALS OF HEMATOLOGY
  • 2009-03-17 Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine in ANNALS OF HEMATOLOGY
  • 2009-01-22 The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence in LEUKEMIA
  • 2009-01-20 Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2009-01-16 Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes in ANNALS OF HEMATOLOGY
  • 2009 Anemia, Sideroblastic Acquired Idiopathic in ENCYCLOPEDIA OF MOLECULAR MECHANISMS OF DISEASE
  • 2008-12-04 Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy in LEUKEMIA
  • 2008-07-10 High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia in LEUKEMIA
  • 2008-06-27 Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2008-06-12 Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes in LEUKEMIA
  • 2007-11-27 MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 × 109/l in ANNALS OF HEMATOLOGY
  • 2007-02-01 Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification in LEUKEMIA
  • 2007-01-25 Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase in LEUKEMIA
  • 2006-10 Myelodysplastische Syndrome in BEST PRACTICE ONKOLOGIE
  • 2006-08-24 The JAK2 V617F mutation is rare in RARS but common in RARS-T in LEUKEMIA
  • 2006-04-13 The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow in LEUKEMIA
  • 2005-11-04 Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia in ANNALS OF HEMATOLOGY
  • 2005-09-29 Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) in LEUKEMIA
  • 2005-04-04 Distinct molecular phenotype of malignant CD34+ hematopoietic stem and progenitor cells in chronic myelogenous leukemia in ONCOGENE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5288.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.84393.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.446907.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411095.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14778.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.1006.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.467675.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.280502.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.120073.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7700.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6292.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.16872.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.24704.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.24381.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419971.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.38142.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7839.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.1055.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419481.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.13097.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.59734.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410458.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.46699.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411088.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.468198.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6363.0", 
            "type": "Organization"
          }
        ], 
        "familyName": "Gattermann", 
        "givenName": "Norbert", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-06-01T22:53", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/person/person_89.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01273447501.34'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01273447501.34'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01273447501.34'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01273447501.34'


     

    This table displays all metadata directly associated to this object as RDF triples.

    70 TRIPLES      10 PREDICATES      38 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01273447501.34 schema:affiliation N1bd0f8bb439d43af87b50fa765a1d0f4
    2 grid-institutes:grid.1006.7
    3 grid-institutes:grid.1055.1
    4 grid-institutes:grid.120073.7
    5 grid-institutes:grid.13097.3c
    6 grid-institutes:grid.14778.3d
    7 grid-institutes:grid.16872.3a
    8 grid-institutes:grid.24381.3c
    9 grid-institutes:grid.24704.35
    10 grid-institutes:grid.280502.d
    11 grid-institutes:grid.38142.3c
    12 grid-institutes:grid.410458.c
    13 grid-institutes:grid.410569.f
    14 grid-institutes:grid.411088.4
    15 grid-institutes:grid.411095.8
    16 grid-institutes:grid.419481.1
    17 grid-institutes:grid.419971.3
    18 grid-institutes:grid.446907.8
    19 grid-institutes:grid.46699.34
    20 grid-institutes:grid.467675.1
    21 grid-institutes:grid.468198.a
    22 grid-institutes:grid.5288.7
    23 grid-institutes:grid.59734.3c
    24 grid-institutes:grid.6292.f
    25 grid-institutes:grid.6363.0
    26 grid-institutes:grid.7700.0
    27 grid-institutes:grid.7839.5
    28 grid-institutes:grid.84393.35
    29 schema:familyName Gattermann
    30 schema:givenName Norbert
    31 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
    32 schema:sdDatePublished 2022-06-01T22:53
    33 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    34 schema:sdPublisher Neb9a57d9d86e4a56a220058c31bd13cf
    35 sgo:license sg:explorer/license/
    36 sgo:sdDataset persons
    37 rdf:type schema:Person
    38 N1bd0f8bb439d43af87b50fa765a1d0f4 schema:affiliation grid-institutes:grid.411327.2
    39 sgo:isCurrent true
    40 rdf:type schema:OrganizationRole
    41 Neb9a57d9d86e4a56a220058c31bd13cf schema:name Springer Nature - SN SciGraph project
    42 rdf:type schema:Organization
    43 grid-institutes:grid.1006.7 schema:Organization
    44 grid-institutes:grid.1055.1 schema:Organization
    45 grid-institutes:grid.120073.7 schema:Organization
    46 grid-institutes:grid.13097.3c schema:Organization
    47 grid-institutes:grid.14778.3d schema:Organization
    48 grid-institutes:grid.16872.3a schema:Organization
    49 grid-institutes:grid.24381.3c schema:Organization
    50 grid-institutes:grid.24704.35 schema:Organization
    51 grid-institutes:grid.280502.d schema:Organization
    52 grid-institutes:grid.38142.3c schema:Organization
    53 grid-institutes:grid.410458.c schema:Organization
    54 grid-institutes:grid.410569.f schema:Organization
    55 grid-institutes:grid.411088.4 schema:Organization
    56 grid-institutes:grid.411095.8 schema:Organization
    57 grid-institutes:grid.411327.2 schema:Organization
    58 grid-institutes:grid.419481.1 schema:Organization
    59 grid-institutes:grid.419971.3 schema:Organization
    60 grid-institutes:grid.446907.8 schema:Organization
    61 grid-institutes:grid.46699.34 schema:Organization
    62 grid-institutes:grid.467675.1 schema:Organization
    63 grid-institutes:grid.468198.a schema:Organization
    64 grid-institutes:grid.5288.7 schema:Organization
    65 grid-institutes:grid.59734.3c schema:Organization
    66 grid-institutes:grid.6292.f schema:Organization
    67 grid-institutes:grid.6363.0 schema:Organization
    68 grid-institutes:grid.7700.0 schema:Organization
    69 grid-institutes:grid.7839.5 schema:Organization
    70 grid-institutes:grid.84393.35 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...